Format

Send to

Choose Destination
See comment in PubMed Commons below
Toxicol Appl Pharmacol. 2014 Jun 1;277(2):118-23. doi: 10.1016/j.taap.2014.03.017. Epub 2014 Apr 4.

Aspirin-triggered resolvin D1 down-regulates inflammatory responses and protects against endotoxin-induced acute kidney injury.

Author information

1
Center for Research on Environmental Disease, University of Kentucky, Lexington, KY 40536, USA.
2
Center for Biomedical Research, University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA.
3
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, PR China.
4
Graduate Center for Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
5
Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY 40536, USA.
6
Center for Research on Environmental Disease, University of Kentucky, Lexington, KY 40536, USA; Graduate Center for Toxicology, University of Kentucky, Lexington, KY 40536, USA. Electronic address: jian.fu@uky.edu.

Abstract

The presence of endotoxin in blood can lead to acute kidney injury (AKI) and septic shock. Resolvins, the endogenous lipid mediators derived from docosahexaenoic acid, have been reported to exhibit potent anti-inflammatory action. Using a mouse model of lipopolysaccharide (LPS)-induced AKI, we investigated the effects of aspirin-triggered resolvin D1 (AT-RvD1) on inflammatory kidney injury. Administration of AT-RvD1 1h after LPS challenge protected the mice from kidney injury as indicated by the measurements of blood urea nitrogen, serum creatinine, and morphological alterations associated with tubular damage. The protective effects were evidenced by decreased neutrophil infiltration in the kidney indicating reduction in inflammation. AT-RvD1 treatment restored kidney cell junction protein claudin-4 expression, which was otherwise reduced after LPS challenge. AT-RvD1 treatment inhibited endotoxin-induced NF-κB activation and suppressed LPS-induced ICAM-1 and VCAM-1 expression in the kidney. Moreover, AT-RvD1 treatment markedly decreased LPS-induced IL-6 level in the kidney and blocked IL-6-mediated signaling including STAT3 and ERK phosphorylation. Our findings demonstrate that AT-RvD1 is a potent anti-inflammatory mediator in LPS-induced kidney injury, and AT-RvD1 has therapeutic potential against AKI during endotoxemia.

KEYWORDS:

Acute kidney injury; Aspirin-triggered resolvin D1; Endotoxemia; Inflammation; Sepsis

PMID:
24709673
DOI:
10.1016/j.taap.2014.03.017
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center